[Iopromide 370 in coronaroventriculography, versus ioxaglate 320 mg/ml].
Twenty-four patients with angina were included in a prospective randomized trial, comparing a new non-ionic contrast medium--iopromide 370 mgI/ml--versus the ionic low osmolar contrast medium, ioxaglate 320 mgI/ml. Twelve received iopromide 370 and twelve ioxaglate 320 mgI/ml. The main topic of this study was general and cardiac safety. Cardiac safety was monitored by EKG and diastolic and systolic blood pressures. In spite of a bias--5 patients with iopromide 370 had myocardial infarction, versus one with ioxaglate 320--there were fewer adverse effects with iopromide 370. The population of only 24 failed to reveal a statistically significant difference, but the tendency was confirmed by the meta-analysis of this multicentric study.
Petitier
H
H
D000790:Angiocardiography; D003287:Contrast Media; D003327:Coronary Disease / Q000000981:diagnostic imaging; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007472:Iohexol / Q000009:adverse effects / Q000031:analogs & derivatives; D007485:Ioxaglic Acid / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic
D003287:Contrast Media; D007472:Iohexol; C038192:iopromide; D007485:Ioxaglic Acid
Etude de l'iopromide 370 en coronaroventriculographie, versus ioxaglate 320 mgI/ml.